Andrei Miclea
University of Bern
14 Papers
70 Citations
Andrei Miclea is an academic researcher from University of Bern. The author has contributed to research in topics: Multiple sclerosis & Dimethyl fumarate. The author has an hindex of 7, co-authored 14 publications. Previous affiliations of Andrei Miclea include Ruhr University Bochum & National and Kapodistrian University of Athens.
Chat about Author
Papers
A Brief Review of the Effects of Vitamin D on Multiple Sclerosis.
TL;DR: Besides vitamin D supplementation as a potential add-on to long-term immunotherapeutic treatment, a recent laboratory study pointed toward a beneficial effect of vitamin D to improve the efficacy of glucocorticoids in relapse therapy.
Safety and efficacy of dimethyl fumarate in multiple sclerosis: a multi-center observational study.
TL;DR: This study corroborates that DMF is an overall safe and effective drug that reduces relapse rate as well as disability progression in MS patients and establishes the additional parameters predicting DMF response, especially in patients switching from other first-line immunotherapies.
36
Time course of lymphocyte repopulation after dimethyl fumarate-induced grade 3 lymphopenia: contribution of patient age.
Myriam Briner,Maud Bagnoud,Andrei Miclea,Christoph Friedli,Lara Diem,Andrew Chan,Robert Hoepner,Anke Salmen +7 more
TL;DR: The frequency of grade 3 lymphopenia in DMF-treated patients with RRMS is estimated and patient-sided factors influencing the time course of lymphocyte repopulation after DMF withdrawal are characterized, corroborating previous studies.
24
Visual Outcomes of Plasma Exchange Treatment of Steroid-Refractory Optic Neuritis: A Retrospective Monocentric Analysis.
Nic Skorupka,Andrei Miclea,Katarzyna Aleksandra Jalowiec,Christoph Bocksrucker,Nicole Kamber,Andrew Chan,Behrouz Mansouri Taleghani,Robert Hoepner,Anke Salmen +8 more
TL;DR: The study demonstrates significant improvements of VA with PLEX in a cohort of MS patients with steroid-refractory ON with a favorable safety profile, and indicates that high response rates may be due to the timely treatment initiation.